Overview

An Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder

Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and efficacy of vortioxetine, once daily (QD), in treating Generalized Anxiety Disorder.
Phase:
Phase 3
Details
Lead Sponsor:
Takeda
Collaborator:
H. Lundbeck A/S
Treatments:
Vortioxetine